Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 465

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 465
---
 Islands. (6)Consists of (i) 721,563shares of New Profusa Common Stock issuable in exchange for Profusa capital stock held by Tasly (International) Healthcare Capital Company Limited, (ii) 398,379shares of New Profusa Common Stock issuable upon conversion of convertible notes held by Tasly International BioInv Two Limited, and (iii) 256,658shares of New Profusa Common Stock issuable upon conversion of the Tasly Convertible Debt. These entities are controlled by Tasly Pharmaceutical Group Co Ltd., a Shanghai Stock Exchange listed company. The business address of Tasly (International) Healthcare Capital Company Limited and Tasly International BioInv Two Limited is: Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.

265 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS NorthView See “ NorthView Management’s Discussion and Analysis of Financial Condition and Results of Operations — Related Party Transactions.” Profusa Investor Rights Agreement In May 2018, Profusa entered into an amended and restated investor rights agreement (the “IRA”) with certain holders of its preferred stock and common stock, including certain holders of 5% of its capital stock, and including certain affiliates of its directors, and certain of its executive officers. The IRA provides the holders of Profusa’s convertible preferred stock with certain registration rights, including the right to demand that Profusa files a registration statement or request that their shares be covered by a registration statement that Profusa is otherwise filing. The IRA also provides certain major stockholders with information rights and a right of first refusal with regard to certain issuances of Profusa’s capital stock. The IRA will terminate upon the closing of the merger. Voting Agreement In May 2018, Profusa entered into an amended and restated voting agreement (the “Voting Agreement”) with certain holders of its preferred stock and common stock, including certain holders of 5% of its capital stock, and including certain affiliates of its directors, and certain of its executive officers. Pursuant to the Voting Agreement, certain holders of its preferred stock and common stock have agreed to vote their shares in favor of the election of certain directors and specified transactions approved by the requisite number of the shares of its voting capital stock held by investors party thereto. The Voting Agreement will terminate upon the closing of the merger. Right of First Refusal and Co-Sale Agreement In May 2018, Profusa entered into an amended and rest